Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.

By R. Estacio, B. Jeffers, Nancy Gifford, R. Schrier. Diabetes Care, 2000

718 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/e79f31435b1eecf3a585c587c882749290161677

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. S. Grundy
2. F. Turnbull
3. Xinfang Xie
4. G. Mansia
5. J. Lv
6. J. Wright
7. A. Boulton
8. M. Woodward

Citations in the corpus

• Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. (2016, background): “Four trials had diastolic BP targets below 80 mmHg [24–26,31].”
• Primary Prevention of Cardiovascular Diseases in People With Diabetes Mellitus (2006, background): “In the ABCD (Appropriate Blood Pressure Control in Diabetes) trial, a mean systolic blood pressure of 132 mmHg was achieved in the more intensively treated group; however, no significant reduction in CVD end points occurred, although total mortality rate was reduced (43).”
• 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, result): “There is very solid evidence of a beneficial effect (reduction in macro and microvascular complications) of a greater versus a smaller blood pressure reduction in type 2 diabetic patients as demonstrated by the HOT and UKPDS trials,(311,427) and confirmed by the ABCD studies.(319,422) A recent meta-”
• Retinopathy in diabetes. (2004, unknown): “(ABCD) Trial (3) randomized patients to”
• Tight Blood Pressure Control and Cardiovascular Outcomes Among Hypertensive Patients With Diabetes and Coronary Artery Disease (2010, unknown): “The mean BP achieved was 132/78 mm Hg in the intensive group and 138/86 mm Hg in the moderate BP control groups.(25) The ABCD investigators found that after 5 years, no difference existed between the intensive and moderate groups in the progression of diabetic retinopathy or neuropathy.”
• Diabetic somatic neuropathies. (2004, background): “Recently, the Appropriate Blood Pressure Control in Diabetes (ABCD) trial assessed the effects of intensive versus moderate blood pressure control with either nisoldipine or enalapril and surprisingly failed to prevent progression of DN, retinopathy, and neuropathy (69).”
• Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. (2002, result): “The AASK, with its larger sample size and wider BP separation, extends previous negative findings regarding the level of BP reduction and change in GFR observed in smaller samples of both African Americans and non–African Americans with nonproteinuric kidney disease.(7,39,40) The average rate of dec”